Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ICMT | O60725 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10097620 | 0.90 | ALDH1A1 (0.43) | ALDH1A1TP53MEN1KMT2ARAB9A | |
| SCHEMBL12995600 | 0.90 | ALDH1A1 (0.42) | ALDH1A1TP53MEN1KMT2ARAB9A | |
| SCHEMBL12995603 | 0.90 | ALDH1A1 (0.42) | ALDH1A1TP53MEN1KMT2ARAB9A | |
| SCHEMBL2886247 | 0.89 | TP53 (0.42) | TP53MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL12105813 | 0.88 | KMT2A (0.41) | ALDH1A1TP53MEN1KMT2ARAB9A | |
| SCHEMBL13152378 | 0.88 | MEN1 (0.43) | ALDH1A1TP53MEN1KMT2ARAB9A | |
| SCHEMBL10096404 | 0.87 | NSD2 (0.42) | ALDH1A1TP53MEN1KMT2ARAB9A | |
| SCHEMBL12995683 | 0.87 | TP53 (0.41) | TP53MEN1KMT2ARAB9ACNR2 | |
| SCHEMBL10096453 | 0.85 | MEN1 (0.40) | ALDH1A1TP53MEN1KMT2ARAB9A | |
| SCHEMBL14467111 | 0.84 | ALDH1A1 (0.42) | ALDH1A1TP53MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | ALDH1A1 1497/4885TP53 1262/4885MEN1 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.